Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 134,240 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 134,240 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $1.55, for a total transaction of $208,072.00. Following the sale, the insider directly owned 6,442,653 shares in the company, valued at approximately $9,986,112.15. This trade represents a 2.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $1.56 on Thursday. The company has a market cap of $71.34 million, a PE ratio of -0.95 and a beta of 0.76. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.87. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. The firm’s 50-day simple moving average is $1.61 and its two-hundred day simple moving average is $1.31.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. Research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HOWL. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $409,000. Marshall Wace LLP bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $113,000. Y Intercept Hong Kong Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $92,000. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics in the first quarter worth approximately $79,000. Finally, Nuveen LLC bought a new position in shares of Werewolf Therapeutics in the first quarter worth approximately $71,000. 64.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Bank of America lowered their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. JMP Securities lowered their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.